financetom
Business
financetom
/
Business
/
What's Going On With Ulta Beauty Stock Friday?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
What's Going On With Ulta Beauty Stock Friday?
May 31, 2024 11:58 AM

Ulta Beauty, Inc. ( ULTA ) shares are volatile Friday following better-than-expected earnings results for the first quarter. Here’s a look at what’s going on.

What To Know: Ulta reported financial earnings for the first quarter of fiscal-year 2024 after the market close on Thursday.

The company reported EPS of $6.47 which came in ahead of analyst estimates of $6.22. In addition, Ulta announced revenue of $2.726 billion beating analyst estimates of $2.721 billion.

The company updated their guidance for the fiscal-year 2024. Ulta sees EPS between $25.2 and $26 and net sales from $11.5 billion to $11.6 billion. Originally, Ulta expected EPS from $26.2 to $27 and net sales between 11.7 billion and 11.8 billion.

Analyst Changes: Following the earnings report, several analyst released price target adjustments.

Evercore ISI Group analyst Michael Binetti maintains Ulta Beauty ( ULTA ) with a Outperform and lowers the price target from $630 to $500.

Telsey Advisory Group analyst Dana Telsey maintains Ulta Beauty ( ULTA ) with a Outperform and maintains $500 price target.

Piper Sandler analyst Korinne Wolfmeyer maintains Ulta Beauty ( ULTA ) with an Overweight and lowers the price target from $505 to $498.

BMO Capital analyst Simeon Siegel maintains Ulta Beauty ( ULTA ) with a Market Perform and lowers the price target from $540 to $500.

Related Link: The Analyst Landscape: 18 Takes On Dollar Tree

ULTA Price Action: Ulta shares are currently higher 1.15% and trading at $390 per data from Benzinga Pro.

Image: Photo via Wikimedia Commons

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Amazon Bid to Shake Off EU Large Platform Designation Rejected by Court
Amazon Bid to Shake Off EU Large Platform Designation Rejected by Court
Nov 19, 2025
05:13 AM EST, 11/19/2025 (MT Newswires) -- Amazon's ( AMZN ) attempt to get a court to reject its designation by European regulators as a very large online platform was rejected Wednesday by a top European court. The European Commission designated Amazon ( AMZN ) an exceptionally large platform of more than 45 million users with special antitrust restrictions and...
DoorDash Shares Surge Over 2.5% In Pre-Market — Here's Why
DoorDash Shares Surge Over 2.5% In Pre-Market — Here's Why
Nov 19, 2025
DoorDash Inc. ( DASH ) shares rose 2.56% to $217.5 in pre-market trading on Wednesday, following a new partnership with Family Dollar, a discount retailer with roughly 7,000 U.S. stores. Check out the current price of DASH stock here.  Partnership Details The partnership, which was announced on Tuesday, allows customers to use the DoorDash ( DASH ) app to order...
US airline group urges Congress to pay controllers during future shutdowns
US airline group urges Congress to pay controllers during future shutdowns
Nov 19, 2025
WASHINGTON (Reuters) -The head of a trade group representing major U.S. airlines will call on Wednesday for permanently ending aviation disruptions during government shutdowns by ensuring air traffic controllers and other key workers are paid. Airlines for America, the group representing American Airlines, Delta Air Lines, Southwest Airlines, United Airlines and others, will tell a U.S. Senate Commerce Aviation Subcommittee...
GSK, LTZ Therapeutics to Collaborate on Myeloid Cell Engagers for Oncology
GSK, LTZ Therapeutics to Collaborate on Myeloid Cell Engagers for Oncology
Nov 19, 2025
05:10 AM EST, 11/19/2025 (MT Newswires) -- GSK (GSK) and LTZ Therapeutics said Wednesday they will collaborate on developing up to four potential novel myeloid cell engagers that target haematologic cancers and solid tumors. The deal will give GSK an exclusive option to license global development and commercial rights for the pre-clinical therapies. LTZ will receive an upfront payment of...
Copyright 2023-2026 - www.financetom.com All Rights Reserved